MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 525606 | Name: Meclofenamate sodium hydrate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Meclofenamate sodium is a potent nonsteroidal anti-inflammatory agent, specifically inhibits chemotactic factor-induced human polymorphonuclear leukocyte functions: chemotaxis, degranulation, and generation of superoxide anion radicals. These effects of MSM were found to be dependent upon the concentrations of drug not bound to albumin (free drug), and were caused by its ability to interfere at both a receptor and post-receptor (i.e., a step distal to mobilization of polymorphonuclear leukocyte intracellular Ca2+) level.

Chemical Structure

Meclofenamate sodium hydrate
Meclofenamate sodium hydrate
CAS#67254-91-5 (sodium hydrate)

Theoretical Analysis

MedKoo Cat#: 525606

Name: Meclofenamate sodium hydrate

CAS#: 67254-91-5 (sodium hydrate)

Chemical Formula: C14H12Cl2NNaO3

Exact Mass: 0.0000

Molecular Weight: 336.14

Elemental Analysis: C, 50.02; H, 3.60; Cl, 21.09; N, 4.17; Na, 6.84; O, 14.28

Price and Availability

Size Price Availability Quantity
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
6385-02-0 (sodium) 644-62-2 (free acid) 67254-91-5 (sodium hydrate)
Synonym
CI 583; CI-583; CI583; INF 4668; INF-4668; INF4668; Meclonax; Meclomen; Meclofenamate sodium; Meclodium; Sodium meclophenamate; Sodium meclofenamate; Meclofenamate sodium
IUPAC/Chemical Name
sodium 2-((2,6-dichloro-3-methylphenyl)amino)benzoate hydrate
InChi Key
QHJLLDJTVQAFAN-UHFFFAOYSA-M
InChi Code
InChI=1S/C14H11Cl2NO2.Na.H2O/c1-8-6-7-10(15)13(12(8)16)17-11-5-3-2-4-9(11)14(18)19;;/h2-7,17H,1H3,(H,18,19);;1H2/q;+1;/p-1
SMILES Code
O=C([O-])C1=CC=CC=C1NC2=C(Cl)C=CC(C)=C2Cl.[H]O[H].[Na+]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Meclofenamic acid sodium hydrate is a non-selective gap-junction blocker. Meclofenamic acid sodium hydrate inhibits hKv2.1 and hKv1.1, with IC50 values of 56.0 and 155.9 μM, respectively.
In vitro activity:
Meclofenamic acid inhibited hKv2.1 in a concentration-dependent manner whereas the other three fenamates had weaker or no effect on these channels at a concentration of 100 microM. The estimated IC50 of meclofenamic acid was 56.0 microM for hKv2.1 compared an IC50 of 155.9 microM for another human neuronal K channel (hKv1.1). Reference: Eur J Pharmacol. 1999 Aug 13;378(3):349-56. https://pubmed.ncbi.nlm.nih.gov/10493112/
In vivo activity:
Tumors were created in a nude mouse model using PC3 cancerous human cells. Meclofenamic acid (10 mg/kg/day; experimental group, n=5) or saline solution (control group, n=5) was administered intraperitoneally for twenty days. Meclofenamic acid causes histological changes that indicate less tumor aggression (less hypercellularity, fewer atypical mitoses, and fewer nuclear polymorphisms), an increase in fibrosis, and reduced cellular proliferation and tumor vascularity. Reference: Int Braz J Urol. 2015 Sep-Oct;41(5):1002-7. https://pubmed.ncbi.nlm.nih.gov/26689527/

Preparing Stock Solutions

The following data is based on the product molecular weight 336.14 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Huang Y, Yan J, Li Q, Li J, Gong S, Zhou H, Gan J, Jiang H, Jia GF, Luo C, Yang CG. Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5. Nucleic Acids Res. 2015 Jan;43(1):373-84. doi: 10.1093/nar/gku1276. Epub 2014 Dec 1. PMID: 25452335; PMCID: PMC4288171. 2. Lee YT, Wang Q. Inhibition of hKv2.1, a major human neuronal voltage-gated K+ channel, by meclofenamic acid. Eur J Pharmacol. 1999 Aug 13;378(3):349-56. doi: 10.1016/s0014-2999(99)00485-9. PMID: 10493112. 3. Delgado-Enciso I, Soriano-Hernández AD, Rodriguez-Hernandez A, Galvan-Salazar HR, Montes-Galindo DA, Martinez-Martinez R, Valdez-Velazquez LL, Gonzalez-Alvarez R, Espinoza-Gómez F, Newton-Sanchez OA, Lara-Esqueda A, Guzman-Esquivel J. Histological changes caused by meclofenamic acid in androgen-independent prostate cancer tumors: evaluation in a mouse model. Int Braz J Urol. 2015 Sep-Oct;41(5):1002-7. doi: 10.1590/S1677-5538.IBJU.2013.00186. PMID: 26689527; PMCID: PMC4756978. 4. Soriano-Hernandez AD, Madrigal-Pérez D, Galvan-Salazar HR, Martinez-Fierro ML, Valdez-Velazquez LL, Espinoza-Gómez F, Vazquez-Vuelvas OF, Olmedo-Buenrostro BA, Guzman-Esquivel J, Rodriguez-Sanchez IP, Lara-Esqueda A, Montes-Galindo DA, Delgado-Enciso I. Anti-inflammatory drugs and uterine cervical cancer cells: Antineoplastic effect of meclofenamic acid. Oncol Lett. 2015 Oct;10(4):2574-2578. doi: 10.3892/ol.2015.3580. Epub 2015 Aug 7. PMID: 26622892; PMCID: PMC4580029.
In vitro protocol:
1. Huang Y, Yan J, Li Q, Li J, Gong S, Zhou H, Gan J, Jiang H, Jia GF, Luo C, Yang CG. Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5. Nucleic Acids Res. 2015 Jan;43(1):373-84. doi: 10.1093/nar/gku1276. Epub 2014 Dec 1. PMID: 25452335; PMCID: PMC4288171. 2. Lee YT, Wang Q. Inhibition of hKv2.1, a major human neuronal voltage-gated K+ channel, by meclofenamic acid. Eur J Pharmacol. 1999 Aug 13;378(3):349-56. doi: 10.1016/s0014-2999(99)00485-9. PMID: 10493112.
In vivo protocol:
1. Delgado-Enciso I, Soriano-Hernández AD, Rodriguez-Hernandez A, Galvan-Salazar HR, Montes-Galindo DA, Martinez-Martinez R, Valdez-Velazquez LL, Gonzalez-Alvarez R, Espinoza-Gómez F, Newton-Sanchez OA, Lara-Esqueda A, Guzman-Esquivel J. Histological changes caused by meclofenamic acid in androgen-independent prostate cancer tumors: evaluation in a mouse model. Int Braz J Urol. 2015 Sep-Oct;41(5):1002-7. doi: 10.1590/S1677-5538.IBJU.2013.00186. PMID: 26689527; PMCID: PMC4756978. 2. Soriano-Hernandez AD, Madrigal-Pérez D, Galvan-Salazar HR, Martinez-Fierro ML, Valdez-Velazquez LL, Espinoza-Gómez F, Vazquez-Vuelvas OF, Olmedo-Buenrostro BA, Guzman-Esquivel J, Rodriguez-Sanchez IP, Lara-Esqueda A, Montes-Galindo DA, Delgado-Enciso I. Anti-inflammatory drugs and uterine cervical cancer cells: Antineoplastic effect of meclofenamic acid. Oncol Lett. 2015 Oct;10(4):2574-2578. doi: 10.3892/ol.2015.3580. Epub 2015 Aug 7. PMID: 26622892; PMCID: PMC4580029.
1: Ghosh R, Hwang SM, Cui Z, Gilda JE, Gomes AV. Different effects of the nonsteroidal anti-inflammatory drugs meclofenamate sodium and naproxen sodium on proteasome activity in cardiac cells. J Mol Cell Cardiol. 2016 May;94:131-44. doi: 10.1016/j.yjmcc.2016.03.016. Epub 2016 Apr 3. PubMed PMID: 27049794. 2: Mongini F, Bona G, Garnero M, Gioria A. Efficacy of meclofenamate sodium versus placebo in headache and craniofacial pain. Headache. 1993 Jan;33(1):22-8. PubMed PMID: 8436494. 3: Benassi L, Bertani D, Avanzini A. An attempt at real prophylaxis of primary dysmenorrhea: comparison between meclofenamate sodium and naproxen sodium. Clin Exp Obstet Gynecol. 1993;20(2):102-7. PubMed PMID: 8330429. 4: Conroy MC, Randinitis EJ, Turner JL. Pharmacology, pharmacokinetics, and therapeutic use of meclofenamate sodium. Clin J Pain. 1991;7 Suppl 1:S44-8. Review. PubMed PMID: 1810520.

View History

Retaspimycin

Retaspimycin